• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Alcon to block Mylan's bid for generic glaucoma med



Ft. Worth, TX-Alcon Research Ltd. has filed suit against Mylan Inc. to stop the pharmaceutical company from launching a generic form of Alcon’s Travatan Z.

The complaint states Mylan has sought FDA approval for its new drug application for eye drops containing the active ingredient travoprost-a product almost identical to Travatan Z-before the patents had expired.

Alcon says it was notified by Mylan in June that the generic-drug manufacturer had filed an application for FDA approval of an ophthalmic solution that contained “the same or equivalent ingredients in the same or equivalent amounts” as Travatan Z.

The patents covering the drug are less than 1 year old. Two patents were issued in September and December 2012, and the third was just approved in March, according to the suit.

Related Videos
Andy Morgenstern, OD, FAAO, FNAP chats with Optometry Times
R Tracy Williams, OD, FAAO with Optometry Times
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Cecelia Koetting, OD, FAAO, DIPABO, left, speaks with Optometry Times about the 2024 EnVision Summit
Bonnie An Henderson, MD, highlights key takeaways of the 2024 EnVision Summit, including diversity and family inclusion
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
Robert Weiss, former CEO and President of The Cooper Companies, Inc. (left) and Optometry Times' Assistant Managing Editor Emily Kaiser Maharjan Image Credit ©Optometry Times
© 2024 MJH Life Sciences

All rights reserved.